|Videos|December 13, 2021
Expert: Chronic Lymphocytic Leukemia Can Effect Younger Individuals
Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses how common chronic lymphocytic leukemia is for younger individuals
Advertisement
In a Pharmacy Times® Interview, Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses his oral presentation at ASH 2021 of the Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia (CLL).
He discussed how common CLL is for younger individuals.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
Enlicitide Meaningfully Lowers LDL-C at 24 Weeks in Patients At Risk for ASCVD Events
3
Evaluating Pharmacists’ Role In Veterinary Medication Management and Education
4
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
5